A New Test Could Improve Diagnosis of Male Infertility and Advance Fertility Treatment

WASHINGTON, Jan. 21, 2022 /PRNewswire/ -- Breaking research published today in AACC's Clinical Chemistry journal shows that a new test can measure the amount of DNA damage in sperm with greater accuracy than current tests. This new method could significantly improve diagnosis of male infertility, which is more important than ever now that infertility rates are mounting.

View the full study here: https://doi.org/10.1093/clinchem/hvab280

Due to a number of factors such as the widespread use of hormone-altering chemicals, infertility has been climbing at an alarming rate worldwide. The global incidence of infertility is now 10%-15%, with male factor infertility accounting for 40% of these cases. The rise in male infertility in particular has led to a need for better ways to assess sperm DNA damage, as this information plays a crucial role in guiding fertility treatments and in selecting high-quality sperm for sperm banks. However, current tests only show whether or not sperm have DNA damage; these tests don't measure the amount of damage, even though the latter is essential for a complete evaluation of sperm health.

To address this issue, a team of researchers led by Xianjin Xiao, PhD, of Tongji Medical College in Wuhan, China, developed a method that detects the number of DNA breaks in sperm, which in turn enables the calculation of the mean number of DNA breaks (MDB) per sperm in a sample. The researchers first evaluated this method using sperm samples from 80 patients, 34 of whom had athenospermia (low sperm motility) and 46 of whom had normal semen. Xiao's team compared the ability of MDB to differentiate between athenospermia and normal samples with that of a conventional sperm DNA test that assesses the sperm DNA fragmentation index (DFI). From this, the researchers found that the area under the curve of MDB (0.7932) was higher than that of DFI (0.7631), meaning that MDB did a better job of telling the two sample types apart.

To further evaluate MDB's clinical utility, Xiao's team then used it and DFI to assess 49 semen samples, 22 of which were associated with pregnancy and 27 of which were linked to an inability to get pregnant. The researchers found that the difference in MDB between the pregnant and non-pregnant groups was statistically significant (P=0.0106), while the difference in DFI between the two groups was not significant (P=0.0548). Furthermore, the area under the curve of MDB in this case (0.7576) was once again higher than the area under the curve of DFI (0.6616). Taken altogether, this means that MDB identifies viable sperm that lead to pregnancy with greater accuracy than conventional sperm DNA tests.

"These data indicated that the MDB parameter had stronger clinical relevance with the pregnancy outcomes and our established method could provide a better tool to evaluate sperm quality and male fertility," said Xiao. "Our method involves direct detection of actual DNA fragmentation, which can measure the specific degree of sperm DNA fragmentation. The method has the advantages of short time-consumption, simple operation, high analytical sensitivity, and low requirement for instruments, which are conducive to the popularization of clinical application."

About AACC
Dedicated to achieving better health through laboratory medicine, AACC brings together more than 50,000 clinical laboratory professionals, physicians, research scientists, and business leaders from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of progressing laboratory science. Since 1948, AACC has worked to advance the common interests of the field, providing programs that advance scientific collaboration, knowledge, expertise, and innovation. For more information, visit www.aacc.org.

Clinical Chemistry (clinchem.org) is the leading international journal of laboratory medicine, featuring nearly 400 peer-reviewed studies every year that help patients get accurate diagnoses and essential care. This vital research is advancing areas of healthcare ranging from genetic testing and drug monitoring to pediatrics and appropriate test utilization. 

Christine DeLong
AACC
Senior Manager, Communications & PR
(p) 202.835.8722
[email protected]

Molly Polen
AACC
Senior Director, Communications & PR
(p) 202.420.7612
(c) 703.598.0472
[email protected] 

SOURCE AACC

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED